Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment(2022)

CME Available: https://auau.auanet.org/node/36065

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Discuss new FDA approved checkpoint inhibitors for treatment and counseling of advanced renal cell carcinoma.

2. Identify indications, risks and benefit of neoadjuvant tyrosine kinase inhibitors for downsizing renal cell carcinoma.

3. Identify appropriate treatment options for management of complex cases.